Scientific, Economic, and Clinical Perspectives on Antimicrobial Resistance
Clinical Aspects by Niels Frimodt-Møller:
The prevalence of antimicrobial resistance (AMR) is increasing world-wide and faster in some areas than others. The main concern is the failure to treat serious infections with antibiotics, the more resistance the fewer available drugs. The consequence is increasing mortality, infectious complications, duration of hospital stay and associated costs to society. Multi-resistant organism demand isolation of affected patients in hospitals, which has serious psychological and physical consequences for each patient. AMR drives the use of still more broad-spectrum antibiotics, which again drives selection of more resistance, a vicious circle which we need to acknowledge in our efforts to curb the menace.
Mining soils for drugs – Microbes as source for novel antibiotics:
The discovery and development of novel antibiotics is an important pillar to fight Antimicrobial Resistance. Famous – and widely used – antibiotics, such as tetracycline, erythromycin or vancomycin, are all originating from soil bacteria and are produced in large scale by fermentation. In this lecture, Tilmann will give examples of Omics- and CRISPR-based approaches to identify, study and produce new bacterial bioactive compounds with potential to be future antibiotic drugs and how these approaches can also help us to understand the origin of several genes leading to antimicrobial resistance in clinical pathogens.
Facts
Programme
Q&A – Virtual participants can ask questions through the chat
Q&A – Virtual participants can ask questions through the chat
Q&A – Virtual participants can ask questions through the chat
